Haloperidol, clonidine and resolution of delirium in critically ill patients: a prospective cohort study.

PURPOSE: Haloperidol and clonidine are commonly used to treat agitation in delirious intensive care unit (ICU) patients, but it is unclear whether these agents may shorten the duration of delirium. The objective of this study was to determine whether haloperidol, clonidine, or their combined administration to delirious ICU patients results in delirium resolution.
METHODS: This was a cohort study on a mixed ICU, excluding patients with a primary neurological disorder. The main outcome was the probability of delirium resolution, using propensity score matching and Markov multinomial logistic regression models for daily transitions. Secondary outcomes were delirium duration, number of delirium days, ventilation days, length of stay in the ICU and hospital, and ICU mortality.
RESULTS: A total of 3614 patients were included (1165 delirious [32%]; 2449 non-delirious [68%]). Delirium occurred on 4708 (18.9%) of 24,906 days. The probability of delirium resolution was lower in delirious patients who received haloperidol (OR 0.47, 95% CI 0.39-0.57), clonidine (OR 0.78, 95% CI 0.63-0.97), or both (OR 0.45, 95% CI 0.36-0.56) compared to untreated delirious patients. Delirious patients who received haloperidol, clonidine, or both had generally longer delirium duration, more delirium and ventilation days, and spent more time in the ICU and in hospital than untreated delirious patients. These agents had no effect on ICU mortality.
CONCLUSION: Haloperidol and clonidine use in delirious ICU patients may be associated with reduced probability of delirium resolution. This finding, however, merits further investigation given inherent limitations of this observational analysis.

Take-home message

Introduction

Delirium is a clinical manifestation of acute encephalopathy and a frequent complication in critically ill patients [1-4]. Patients who experience delirium during intensive care unit (ICU) admission are more likely to have a longer stay in the ICU and hospital, and are more likely to incur higher healthcare costs than patients without delirium [5, 6]. Delirium is further associated with an increased risk of long-term cognitive impairment [7, 8]. However, managing delirium remains a challenge for ICU physicians as an established treatment is lacking [9].

Pharmacological management of delirium is currently based on inferences of presumed pathophysiology. A widely used drug for treating delirium in a critical care setting is haloperidol, a dopamine D2 antagonist [10]. However, little evidence is available to support its use in treatment of all patients with delirium [9]. Two randomized trials have studied the efficacy of haloperidol versus placebo as treatment of ICU delirium. One was a pilot trial conducted in mechanically ventilated patients admitted to a medical or surgical ICU [11], and the other was a therapeutic trial in patients with acute respiratory failure or shock [12]. These trials have shown that haloperidol does not deliver a difference of more than two delirium- and coma-free days when compared to placebo. However, a smaller difference could still be clinically relevant.

In addition to an excess of dopaminergic activity, it has been hypothesized that delirium results from an excess of norepinephrine activity [13]. The release of norepinephrine is inhibited by dexmedetomidine, an alpha-2 agonist, which has recently gained popularity for treating agitated delirium in mechanically ventilated patients [14, 15]. However, it is only available as intravenous preparation and, due to its costs, may not be the preferred agent for all critically ill patients [16]. Clonidine is another alpha-2 agonist that is less expensive and may therefore be an alternative to dexmedetomidine. Clonidine is available in both intravenous and enteral formulations, and is regularly administered to treat agitation in both mechanically ventilated and non-ventilated ICU patients [17]. A randomized controlled pilot trial in cardiothoracic surgery patients showed promising results regarding delirium severity [18]. Yet, to our knowledge no studies have been conducted on the efficacy of clonidine for treatment of delirium in a mixed ICU [19].

We hypothesized that treatment with haloperidol and/or clonidine would increase the likelihood of resolving delirium. The aim of this cohort study was therefore to determine whether administration of haloperidol, clonidine, or their combined use was associated with resolution of delirium in critically ill patients.

Methods

Study design and participants

This study was based on a prospectively enrolled cohort of patients admitted to the mixed ICU of the University Medical Center Utrecht the Netherlands between August 2011–June 2013 and June 2015–March 2019 [20, 21]. In between these two periods no data have been collected, due to lack of available research staff. Details on the patients in the first cohort have been published [22]. For the current analysis, exclusion criteria were ICU admission < 24 h, readmissions, transfers from another ICU, or admission with a primary acute neurological or neurosurgical disorder confounding the delirium diagnosis [23], or another condition that could hamper the assessment of delirium, such as mental retardation, anoxic brain injury after cardiopulmonary resuscitation, or inability to speak Dutch or English. ICU physicians adhered to a sedation protocol aiming for light sedation (target Richmond Agitation and Sedation Scale [RASS] score − 2 to 0), without using dexmedetomidine. Because of the non-interventional nature of this investigation, the ethics committee of the University Medical Center Utrecht waived the need for informed consent (protocol #19-768/c). This cohort study was reported using the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement [24].

Data collection and definitions

All data have been collected prospectively. Age, sex, ICU admission type, Acute Physiology and Chronic Health Evaluation (APACHE) IV [25], and ICU and hospital length of stay were stored in the electronic patient data management system. On a daily level (one day was defined as a 24-h epoch from 10AM to 09.59AM), the following characteristics were collected: modified Sequential Organ Failure Assessment (SOFA) score (without the central nervous system component) [26], presence of metabolic acidosis (defined as base excess < − 3 in arterial blood gas analysis), mechanical ventilation status, mortality, and administration of antipsychotics (haloperidol, quetiapine, olanzapine, clozapine, risperidone), sedatives (benzodiazepines, propofol, clonidine) and opioids.

Patients were prospectively classified per 24-h epoch as awake without delirium, delirious, unarousable, discharged or dead. The daily mental status was classified according to a delirium recognition algorithm based on three items [22]: (1) the RASS and Confusion Assessment Method-Intensive Care Unit (CAM-ICU) scores, assessed by bedside nurses, (2) evaluation of medical charts for signs of delirium i.e. altered consciousness and > 1 symptoms of delirium, and (3) additional delirium assessments by trained researchers. If in a 24-h period at least one of these items was positive for delirium, patients were classified as delirious. In this current cohort study, the initiation of haloperidol or quetiapine was not used to classify patients as delirious. Sedation was assessed every three hours with the RASS [27]. On a daily level, an unarousable state was defined as all RASS scores on that day being < − 3 or − 3 combined with sedative use—impeding delirium assessment [28]. Patients were classified as awake without delirium if they had at least one RASS score > − 4, or > − 3 if in combination with sedative use, in a 24-h period, with all delirium assessments in that period being negative. With regards to delirium during ICU stay, patients were classified as delirious if they had at least one day with a positive delirium assessment according to the before mentioned algorithm.

Outcomes

The primary outcome was transitioning from delirium on any given day (day X) to an awake state without delirium on the following day (day X + 1). Secondary outcomes were delirium duration (in days), number of delirium and ventilation days, length of stay in the ICU and hospital (in days), and ICU mortality. Delirium duration was the number of consecutive days that a patient was classified as delirious or unarousable during the first delirium episode in the ICU. As delirium may fluctuate over time and as patients may transition between delirium and unarousable states during a delirium episode, we defined a delirium episode as ended if the patient was awake without delirium for at least two consecutive days.

Statistical analysis

Continuous data were summarized with medians and interquartile ranges (IQR) or means with standard deviations, depending on distribution. Categorical variables were shown as proportions with percentages. To describe differences between patients who were ever delirious and patients who were never delirious, continuous variables were compared using Mann–Whitney U tests or independent t tests, and categorical outcomes with Chi square tests. For differences in baseline medication exposures, we used logistic and linear regression analyses.

For the primary analysis the delirious observation days were used. We studied whether the administration of haloperidol, clonidine, or both haloperidol and clonidine on any given delirium day (day X) was associated with a transition to an awake state without delirium on the following day (day X + 1), compared to the probability of either remaining delirious or transitioning to unarousable state on day X + 1, with mortality and discharge on day X + 1 being competing events (Online Resource 1). The combination of delirium and unarousable state on the following day was chosen as a comparator, as we specifically aimed to assess delirium resolution as transition to an awake state without delirium and to minimize confounding of the treatment to the delirium assessment due to sedative side-effects of haloperidol [29] and clonidine [30]. For the primary analysis we used a first-order Markov multinomial logistic regression model. Model 1 involved administration of haloperidol only (yes/no), clonidine only (yes/no), or both haloperidol and clonidine (yes/no) on day X. Additionally, to examine dose-dependency, we modeled two main predictors (Model 2): (1) dosage of intravenously administered haloperidol in milligrams on day X, with a conversion of 0.6 per milligram enterally administered haloperidol based on bioavailability, and (2) dosage of intravenously administered clonidine in micrograms on day X. To control for confounding, we included the following covariates to both Markov models: age, APACHE IV score, and admission type (acute surgery, elective surgery, medicine). Additionally, we included the following daily covariates: patients’ mental status on day X, modified SOFA score, metabolic acidosis (yes/no), use of mechanical ventilation (yes/no), and administration of any antipsychotic other than haloperidol (yes/no), benzodiazepines or propofol (yes/no), and opioids (yes/no). These covariates were associated with delirium development, or were suspected to confound the studied association [31].

Additionally, we used propensity score matching for the primary analysis to match delirium days without medication exposure with delirium days on which haloperidol, clonidine, or both was administered. The match tolerance was set to 0.001. We adjusted for confounding by including the same covariates as in the Markov models.

Three sensitivity analyses were performed. First, as both haloperidol and clonidine may have mild sedative effects [29, 30], they may influence the CAM-ICU assessment. Likewise, agitated delirious patients may have received more haloperidol and/or clonidine than patients with hypoactive delirium. Hence, our first sensitivity analysis stratified outcomes by delirium motor subtypes, comparing “hyperactive delirium days” (all RASS scores on that delirium day > 0), “hypoactive delirium days” (all RASS scores on that delirium day ≤ 0) and “mixed delirium days” (RASS scores of both > 0 and ≤ 0 on that delirium day). Second, we assessed whether the implementation of the 2013 Pain, Agitation and Delirium guideline [32] and general changes in ICU delirium management over the years affected the resolution of delirium by assessing the effect of the inclusion period (2011–2013 versus 2015–2019). Third, as the clinical effects of haloperidol and clonidine may become apparent 24 h after administration, we examined whether there was an association of the administration of haloperidol and/or clonidine on delirium day X with transition to an awake state without delirium on day X + 2, using the same analysis as for X + 1.

Secondary analyses were performed on patient level in delirious patients instead of the level of observation-days to assess whether the administration of haloperidol, clonidine or both haloperidol and clonidine versus none of these agents during ICU stay was associated with the secondary outcomes. Linear regression models were used to analyze delirium duration, number of delirium and ventilation days, and ICU and hospital length of stay. ICU mortality was analyzed with a logistic regression model. These models were adjusted for age, APACHE IV score, admission type, highest modified SOFA score during ICU stay, presence of metabolic acidosis during ICU stay (yes/no), ventilation during ICU stay (yes/no), delirium duration (in days), and administration of any antipsychotic other than haloperidol (yes/no), benzodiazepines or propofol (yes/no) and opioids (yes/no) during ICU stay. If needed, log transformation of the variables was performed.

Analyses were performed in SPSS, version 25, and Markov multinomial logistic regression analyses were performed in R, version 3.5.1. To evaluate the goodness of fit, likelihood ratio tests, F values and R2 values were used. Observations were excluded if delirium classification was missing. A two-sided p value less than 0.05 was considered statistically significant.

Results

Study population and observation days

During the study periods, 12,380 patients were admitted to the ICU. After applying inclusion and exclusion criteria, we included 3614 patients (details outlined in Online Resource 2). Among these, 1165 (32%) experienced delirium during ICU stay and were used for the analyses. The median age was 63 years (IQR 52–72) and 2286 (63.3%) were male (Table 1). Patients with delirium were significantly older, had a higher APACHE IV score, and were more often admitted with a medical or an acute surgical diagnosis than patients without delirium.

Table 1

Characteristics of included patients, stratified by delirium status during ICU stay

Characteristic	All patients (n = 3614)	Ever delirious (n = 1165)	Never delirious (n = 2449)	p valuea
Age, years (IQR)	63 (52–72)	64 (54–73)	63 (51–71)	< 0.001
Male, n (%)	2286 (63.3%)	763 (65.5%)	1523 (62.2%)	0.055
ICU admission type
Acute surgery, n (%)b	700 (19.4%)	319 (27.4%)	381 (15.6%)	< 0.001
Elective surgery, n (%)b	1688 (46.7%)	359 (30.8%)	1329 (54.3%)	< 0.001
Medicine, n (%)b	1224 (33.9%)	487 (41.8%)	737 (30.1%)	< 0.001
APACHE IV score (IQR)b	54 (39–74)	69 (53–87)	47 (35–64)	< 0.001
ICU LOS, days (IQR)	2.6 (1.2–5.9)	6.8 (3.7–13.1)	1.8 (1.1–3)	< 0.001
Hospital LOS, days (IQR)	13.3 (7.1–25.9)	24.2 (14–42.9)	9.9 (6–218.3)	< 0.001
Mechanical ventilation, ever, n (%)b	3374 (93.4%)	1135 (97.7%)	2239 (91.9%)	< 0.001
ICU mortality, n (%)	345 (9.5%)	139 (11.9%)	206 (8.4%)	0.001

APACHE IV Acute Physiology and Chronic Health Evaluation IV, ICU Intensive Care Unit, IQR interquartile range, LOS length of stay

aDifference between patients who were ever delirious and those who were never delirious

bMissing data were present for some patients: medical ICU admission type 2 (0.1%); acute surgery ICU admission type 2 (0.1%); elective surgery ICU admission type 2 (0.1%), APACHE IV score 190 (5.3%); mechanical ventilation, ever 15 (0.4%)

See Online Resource 3, Table 1 for the characteristics of the observations days. Delirium occurred on 4708 (18.9%) of 24,906 observation days, which were used for the primary analysis. Haloperidol and clonidine were more frequently administered on delirium days than on days in which patients were unarousable or awake without delirium, and more often on mixed/hyperactive delirium days than hypoactive delirium days (Online Resource 3, Table 2).

Table 2

Haloperidol and clonidine use on day X and delirium resolution on the following day

Mental status on day X	Exposure on day X	Mental status on day X + 1	Adjusted OR (95% CI)a	p value
Delirious	No haloperidol or clonidine	Delirious or unarousable	Reference
Delirious	Haloperidol only	Awake without delirium	0.47 (0.39–0.57)	< 0.001
Delirious	Clonidine only	Awake without delirium	0.78 (0.63–0.97)	0.025
Delirious	Both haloperidol and clonidine	Awake without delirium	0.45 (0.36–0.56)	< 0.001

Markov regression model (Model 1). Mortality or discharge on day X + 1 was included as a competing event. The model fitted the data well (χ2(63) = 13,578.841, p < 0.001)

CI confidence interval, OR Odds ratio

aAdjusted for age, APACHE IV score, admission type (acute surgery, elective surgery, medical reason), patients’ mental status on day X, modified SOFA score, metabolic acidosis, use of ventilation, and administration of any antipsychotic other than haloperidol, benzodiazepines, propofol and opioids

No values were missing for the predictors. For the covariates, values were missing for ICU admission type (0.1%), APACHE IV score (5.3%), modified SOFA score (3.9%) and patients’ mental status on day X (14.2%).

Daily transitions and administration of haloperidol and clonidine

From the 4708 delirium days, 1101 (23.4%) patients transitioned to an awake state without delirium the following day, while 2712 (57.6%) remained delirious and 269 (5.7%) transitioned to an unarousable state. Additionally, 509 (10.8%) were discharged or died, and from 117 (2.5%) the mental status on the following day was missing. The transition flow including data on the receipt of haloperidol and clonidine is shown in Fig. 1. Patients in whom delirium resolved the following day were administered haloperidol and/or clonidine less frequently and in lower dosages than patients who remained delirious or transitioned to an unarousable state.

Fig. 1

Daily transitions of mental status including administration of haloperidol and clonidine on delirium day X with median dosages. CI confidence interval, IQR interquartile range, Mcg microgram, Mg milligram, OR Odds ratio. a509 (10.8%) patients were deceased or discharged on day X + 1 and for 117 (2.5%) patients the mental status on the following day was missing. bSignificant (p < 0.001) difference in frequency of administration as compared to delirium or unarousable on day X + 1, tested with logistic regression models, adjusted for age, APACHE IV score, admission type (acute surgery, elective surgery, medical reason), patients’ mental status on day X, modified SOFA score, metabolic acidosis, use of ventilation, and administration of any antipsychotic other than haloperidol, benzodiazepines, propofol and opioids. Adjusted OR (95%CI) for haloperidol only was 0.66 (0.55–0.78) and for both haloperidol and clonidine 0.59 (0.48–0.73). cSignificant (p < 0.05) difference in dose of administered medication as compared to delirium or unarousable on day X + 1, tested with linear regression models, adjusted for age, APACHE IV score, admission type (acute surgery, elective surgery, medical reason), patients’ mental status on day X, modified SOFA score, metabolic acidosis, use of ventilation, and administration of any antipsychotic other than haloperidol, benzodiazepines, propofol and opioids. Adjusted OR (95% CI) for haloperidol only was 0.96 (0.93–0.98), for clonidine only 0.88 (0.83–0.93), for haloperidol in case of both haloperidol and clonidine administration 0.95 (0.92–0.98) and for clonidine in case of both haloperidol and clonidine administration 0.9 (0.85–0.95)

Markov modeling and propensity score matching of haloperidol and clonidine administration and delirium resolution

As shown in Table 2, the administration of haloperidol on a delirium day was associated with significant lower odds of delirium resolution on the following day (OR 0.47; 95% CI 0.39–0.57), as was administration of clonidine (OR 0.78; 95%CI 0.63–0.97) and the use of both haloperidol and clonidine (OR 0.45; 95% CI 0.36–0.56). Propensity score matching yielded similar results as our primary analyses (Online Resource 4).

Further, the odds ratio of delirium resolution was 0.84 (95% CI 0.81–0.88) for every 1 mg administered haloperidol, and 0.98 (95% CI 0.97–1) per 100 µg clonidine (Model 2, Table 3).

Table 3

Haloperidol and clonidine dosage on day X and delirium resolution on the following day

Mental status on day X	Exposure on day X	Mental status on day X + 1	Adjusted OR (95% CI)a	p value
Delirious	No haloperidol or clonidine	Delirious or unarousable	Reference
Delirious	Haloperidol dose (per 1 mg in 24 h)	Awake without delirium	0.84 (0.81–0.88)	< 0.001
Delirious	Clonidine dose (per 0.1 mg in 24 h)	Awake without delirium	0.98 (0.97–1)	0.023

Markov regression model (Model 2). Mortality or discharge on day X + 1 was included as a competing event. Model fit: χ2(54) = 13,529.869, p < 0.001

CI confidence interval, Mg milligram, OR Odds ratio

aAdjusted for age, APACHE IV score, admission type (acute surgery, elective surgery, medical reason), patients’ mental status on day X, modified SOFA score, metabolic acidosis, use of ventilation, and administration of any antipsychotic other than haloperidol, benzodiazepines, propofol and opioids

The results of the three sensitivity analyses are reported in Online Resource 5. First, due to the low number of hyperactive delirium days, we analyzed these days together with mixed delirium days. The use of haloperidol or both haloperidol and clonidine on a hyperactive/mixed or hypoactive delirium day was associated with significantly lower odds on delirium resolution, while clonidine was not. Second, similar findings were obtained for the inclusion periods 2011–2013 and 2015–2019, with administration of clonidine only being associated with lower odds of delirium resolution for inclusion period 2015–2019 only. Last, lower probabilities of delirium resolution on day X + 2 were found for haloperidol only and both haloperidol and clonidine, but not for clonidine only.

Secondary outcomes

As shown in Table 4, the administration of haloperidol, clonidine, or both haloperidol and clonidine in delirious patients was associated with increased delirium duration, more delirium days, and a longer stay in the ICU. These patients also spent more time in the hospital than untreated delirious patients, with exception for patients who were administered clonidine only. Additionally, the number of ventilation days was higher in patients who were administered both haloperidol and clonidine. There was no difference in ICU mortality.

Table 4

Secondary outcomes in delirious patients from administration of haloperidol, clonidine or both during ICU stay

Secondary outcome	Exposure during ICU stay	Adjusted exp(B)	95% CI	p value
Delirium durationa,b	No haloperidol or clonidine	Reference
	Clonidine only	1.08	1.02–1.16	0.015
	Haloperidol only	1.27	1.19–1.35	< 0.001
	Both haloperidol and clonidine	1.44	1.36–1.52	< 0.001
Delirium daysa,b	No haloperidol or clonidine	Reference
	Clonidine only	1.05	1–1.1	0.040
	Haloperidol only	1.23	1.17–1.28	< 0.001
	Both haloperidol and clonidine	1.3	1.24–1.35	< 0.001
Ventilation daysa,b	No haloperidol or clonidine	Reference
	Clonidine only	1.06	0.99–1.13	0.108
	Haloperidol only	1	0.94–1.07	0.920
	Both haloperidol and clonidine	1.11	1.04–1.17	0.001
ICU LOSa,b	No haloperidol or clonidine	Reference
	Clonidine only	1.06	1–1.13	0.043
	Haloperidol only	1.07	1.01–1.13	0.017
	Both haloperidol and clonidine	1.16	1.1–1.22	< 0.001
Hospital LOSa,b	No haloperidol or clonidine	Reference
	Clonidine only	1.02	0.98–1.09	0.519
	Haloperidol only	1.07	1–1.13	0.042
	Both haloperidol and clonidine	1.11	1.05–1.18	< 0.001
ICU mortalityb,c	No haloperidol or clonidine	Reference
	Clonidine only	0.47	0.22–1.03	0.059
	Haloperidol only	1.16	0.6–2.21	0.665
	Both haloperidol and clonidine	0.65	0.35–1.2	0.169

Regression models adjusted for age, APACHE IV score, admission type, highest modified SOFA score during ICU stay, presence of metabolic acidosis during ICU stay, ventilation during ICU stay, administration of any antipsychotic other than haloperidol, benzodiazepines, propofol and opioids during ICU stay, and delirium duration

CI confidence interval, ICU Intensive Care Unit, LOS length of stay, OR Odds ratio

aLinear regression after log transformation due to skewed distribution of residuals

bModel is a good fit to the data. Delirium duration: F(12,1002) = 37.532, p < 0.0001, R2 = 0.310; delirium days: F(13,1071) = 124.531, p < 0.001, R2 = 0.602; ventilation days: F(12,1045 = 58.617, p < .001, R2 = 0.402; ICU LOS: F(13,1071) = 71.937, p < 0.001, R2 = 0.466; Hospital LOS: F(13,1071) = 20.792, p < 0.001, R2 = 0.202; ICU mortality: Hosmer and Lemeshow test p = 0.545

cLogistic regression analysis

Discussion

In summary, our study suggests that treatment of ICU delirium with haloperidol, clonidine, or both haloperidol and clonidine might reduce the probability of delirium resolution. These associations were dose-dependent, and consistent with almost all secondary outcomes.

Our findings with regards to haloperidol as delirium treatment are in line with previous observational studies, in which higher delirium rates were found with haloperidol use [33]. In non-intubated patients, each additional milligram of haloperidol was associated with 5% higher odds of delirium on the following day [34]. Another retrospective study found that treatment of delirious patients with antipsychotics (quetiapine, olanzapine, risperidone or haloperidol) was associated with a longer delirium duration and ICU stay [35]. However, our observations that haloperidol might be associated with reduced probability of delirium resolution and increased delirium duration are partly in contrast with two recent randomized controlled trials [12, 36]. These trials found that haloperidol is not associated with prevention or resolution of delirium, and the number of delirium days. These differences may be explained by our time-dependent Markov analysis focusing on daily transitions, instead of the number of delirium days in a certain (limited) study period. We found that the use of haloperidol and clonidine on delirium days was associated with reduced probabilities of delirium resolution within 48 h after administration. It might be that these agents have negative short-term effects on delirium resolution, but that these effects will disappear after 48 h or more. Second, our results may differ due to differences in study populations and dosage regimens. We had a high percentage of surgical patients (66.1%) as compared to 28% in the study by Girard et al. [12]. Finally, the optimal dosage of haloperidol and/or clonidine as delirium treatment remains unknown. Despite the dose-dependent association shown in our cohort, the dosages might have been too low to deliver a positive effect on delirium resolution.

The efficacy of clonidine, alone or in combination with haloperidol, as ICU delirium treatment has been studied less extensively, possibly because intravenous clonidine is not available in the United States. A small placebo-controlled prevention trial in patients who underwent surgical correction of acute type-A aortic dissection showed no beneficial effect of intravenous clonidine on delirium incidence, but did report lower delirium severity [18]. Our results may challenge clonidine as treatment in all patients with delirium. However, confirmation in a randomized trial or another cohort study is warranted.

While we had expected that treatment with haloperidol and/or clonidine would increase the likelihood of resolving delirium, our results do not support this. An explanation may be that haloperidol and clonidine induce hypoactive symptoms, and thereby interfere with delirium assessment. However, haloperidol and clonidine dosages in our cohort were relatively low. Subsequently, the probability of false positive delirium assessments due to sedative effects of these drugs is likely to be low. In addition, our primary outcome comparator involved a combination of delirium and unarousable state and not exclusively delirium, and the validated delirium algorithm that was used to classify delirium was based on a comprehensive assessment of several other symptoms of delirium [22].

A few other limitations should be considered. First, this was a single-center observational study in patients who were mostly mechanically ventilated, which may limit generalizability. Second, classifying a patients’ mental status as being either awake without delirium, delirium or unarousable on a daily basis may be a simplification, as mental status may not be categorizable and delirium may fluctuate over the course of the day. Similarly, some delirious patients may have experienced rapidly reversible, sedation-related delirium, which seem to have a prognosis similar to that seen in non-delirious patients [37, 38]. Third, we did not examine whether haloperidol and clonidine were associated with reduction of psychotic features and agitation. Hence, we are not able to make any recommendations regarding treatment of such features. A last important methodological concern is that daily transitions of mental states were assumed to be independent of the patient history beyond the prior day. While the covariables were derived from a systematic review [31], it is possible that unmeasured confounding influenced the results. Additionally, despite using propensity scoring to match groups, more patients with severe delirium, and thus a low risk of delirium resolution, may have received haloperidol or clonidine than patients who had lower delirium severity, which can be regarded as confounding by indication. The sensitivity analysis with respect to delirium subtypes may have dealt with any possible confounding by delirium motor subtypes or delirium severity. It would be important to study the treatment effects of haloperidol and clonidine in a future randomized clinical trial.

A key strength is that this study is the first to investigate haloperidol and clonidine as delirium treatment, both separately as well as in combination, in the same study population. We made use of a validated delirium-recognition algorithm that advocated frequent CAM-ICU assessment and incorporated additional criteria to define delirium [22]. Another strength is the large sample size, allowing us to adjust for numerous confounders. Additionally, we could investigate temporal relationships between administration of medication and transitions of mental states, which allowed us to take account of the factors that varied over time during ICU admission.

Conclusion

In conclusion, this large cohort study suggests that administration of haloperidol, clonidine, or both, in delirious ICU patients may be associated with reduced probabilities of short-term delirium resolution and worse short-term clinical outcomes, such as longer delirium episodes and longer ICU stay. However, although adjusted for known confounders, these results should be regarded as hypothesis generating and future studies are needed to inform clinical practice. We suggest that in such studies symptomatic treatment of psychotic features or agitation should be differentiated from delirium diagnosis as a syndrome.

Below is the link to the electronic supplementary material.

Supplementary file1 (PDF 27 KB)

Supplementary file2 (PDF 54 KB)

Supplementary file3 (PDF 62 KB)

Supplementary file4 (PDF 19 KB)

Supplementary file5 (PDF 31 KB)

Delirious ICU patients who are treated with haloperidol, clonidine, or both, were found to have reduced probabilities of delirium resolution and worse short-term clinical outcomes, such as longer delirium duration, ICU and hospital stay, and length of mechanical ventilation. However, due to the observational nature of this analysis, the results should be regarded as hypothesis generating.